They found that the survival time of pancreatic cancer patients with a concentration of serum sMICA below 290 pg/mL was significantly longer than that of other pancreatic cancer patients with a concentration of serum sMICA above 290 pg/mL, and also found that pancreatic cancer patients with high expression of MICA on tumor cells had longer survival times, suggesting that MICA could be a potential therapeutic target for pancreatic cancer [64]. This evidence concerns the gene MICA and familial pancreatic carcinoma.